Loading…
Veradermics, Incorporated is projected to rise to $150.49 by 2027, a +26% move from its current price of $119.60. MANE is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $115.10 | $119.67 | $124.42 | +0.06% |
| Jul 13 | $113.32 | $119.73 | $126.51 | +0.11% |
| Jul 14 | $111.99 | $119.80 | $128.16 | +0.17% |
| Jul 15 | $110.89 | $119.87 | $129.57 | +0.22% |
| Jul 16 | $109.94 | $119.93 | $130.84 | +0.28% |
| Jul 17 | $109.09 | $120.00 | $132.01 | +0.34% |
| Jul 18 | $108.32 | $120.07 | $133.09 | +0.39% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $108.32 | $120.07 | $133.09 | +0.39% |
| Week 2 | $104.20 | $120.54 | $139.44 | +0.79% |
| Week 3 | $101.24 | $121.01 | $144.64 | +1.18% |
| Week 4 | $98.87 | $121.49 | $149.28 | +1.58% |
| Week 5 | $96.87 | $121.96 | $153.55 | +1.97% |
| Week 6 | $95.14 | $122.44 | $157.58 | +2.37% |
| Week 7 | $93.60 | $122.92 | $161.42 | +2.78% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Veradermics, Incorporated is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. Its products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy.
Additionally, it engages in the development of VDMN, a dissolvable microarray patch technology for immunotherapy of common warts; VDAA for the treatment of alopecia areata; and VDMC for the treatment of molluscum contagiosum. Its products are used for the treatment of androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. The company serves healthcare providers and clinicians treating dermatologic and aesthetic conditions in both adult and pediatric populations, as well as the broader medical and clinical research community involved in dermatology.
Veradermics, Incorporated was incorporated in 2019 and is headquartered in New Haven, Connecticut.
Veradermics, Incorporated (MANE) is a healthcare company operating in the dermatology space with a focus on hair loss and dermatologic conditions. The current price is $116.80 and the market cap is $4.88B, with a ranking of 1399 by market capitalization. The current price and market position place it among mid-cap developers in the sector.
The price outlook according to the provided forecasts shows a bullish trajectory over the long term, with the average price rising from $116.80 in 2026 to progressively higher levels, reaching $2,303.99 on average by 2050. The 2026 forecast is neutral, while 2027 through 2050 carry a bullish sentiment.
A major floor 62.3% below — a decisive break under it would weaken the trend.
The nearest floor, 24.5% below — buyers have tended to step in here.
The nearest ceiling, 8.5% above — a clean break opens room to run.
A major ceiling 27.6% above — clearing it would confirm fresh momentum.
Key MANE support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of MANE market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $120.33 | Sell | $121.18 | Sell |
| MA 10 | $123.33 | Sell | $119.77 | Sell |
| MA 20 | $111.99 | Buy | $114.73 | Buy |
| MA 50 | $106.04 | Buy | $103.17 | Buy |
| MA 100 | $83.12 | Buy | $87.95 | Buy |
| MA 200 | — | Neutral | — | Neutral |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 57.24 | Neutral |
| Stoch RSI (14) | 1.78 | Buy |
| CCI (20) | 40.26 | Neutral |
| Williams %R (14) | -37.63 | Info |
| MACD (12,26,9) | 0.15 | Buy |
| ROC (12) | 15.44 | Buy |
| Bollinger %B (20,2) | 0.64 | Neutral |
| Stochastic %K (14) | 62.37 | Neutral |
| TRIX (15) | 0.87 | Buy |
| Awesome (5,34) | 13.82 | Buy |
| Ultimate (7,14,28) | 53.57 | Neutral |
| Momentum (10) | 0.23 | Buy |
| Aroon Osc (25) | 68.00 | Buy |
| Hull MA (9) | 118.90 | Buy |
| ADX (14) | 22.97 | Buy |
| ATR (14) | 4.17 | Info |
The 30-day technical picture is bullish. RSI14 is 60 and the stock sits above a 50-day moving average of $104.21, indicating positive momentum. Key near-term levels are a support at $90.32 and a resistance at $129.74, with the 30-day price range spanning $89.80 to $151.91.
The data also notes an annualized volatility of 80%. The SMA200 value is not provided in the current data.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $37.03 | $119.60 | $174.72 | 0% | Neutral | |
| $107.13 | $150.49 | $228.96 | +26% | Bullish | |
| $117.80 | $177.13 | $288.43 | +48% | Bullish | |
| $130.71 | $208.38 | $357.35 | +74% | Bullish | |
| $165.32 | $278.05 | $497.60 | +132% | Bullish | |
| $198.69 | $351.45 | $652.42 | +194% | Bullish | |
| $226.91 | $421.26 | $807.72 | +252% | Bullish | |
| $229.84 | $447.16 | $882.57 | +274% | Bullish | |
| $222.52 | $453.25 | $918.48 | +279% | Bullish | |
| $248.66 | $529.93 | $1,100.18 | +343% | Bullish | |
| $433.94 | $964.31 | $2,210.53 | +706% | Bullish | |
| $1,068.46 | $2,374.35 | $5,461.00 | +18.9x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $37.03 | $119.60 | $152.62 | +0.00% |
| August 2026 | $105.53 | $128.54 | $163.51 | +7.48% |
| September 2026 | $101.74 | $125.85 | $163.70 | -2.09% |
| October 2026 | $99.74 | $125.04 | $165.72 | -0.65% |
| November 2026 | $101.73 | $129.00 | $173.65 | +3.17% |
| December 2026 | $99.85 | $127.98 | $174.72 | -0.80% |
Click any year to see its month-by-month MANE forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Veradermics, Incorporated's 2026 outlook centres on $119.60, within a $37.03 to $174.72 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, MANE could reach as high as $228.96, with a base case around $150.49 and support toward $107.13 — roughly +26% from $119.60. Buyers look set to stay in control over this stretch.
Expect MANE to range from $117.80 to $288.43 through 2028. The $177.13 average target implies a +48% move from current prices. That is up +18% on the projected 2027 average. Momentum favours further upside here.
The MANE price prediction for 2029 points to an average of $208.38 (low $130.71, high $357.35) — a potential gain of +74% on today's $119.60. Buyers look set to stay in control over this stretch.
In 2030, MANE is projected to trade between $165.32 and $497.60, averaging $278.05 — a potential gain of +132% from today's $119.60. That is up +33% on the projected 2029 average. Momentum favours further upside here.
Veradermics, Incorporated's 2031 outlook centres on $351.45, within a $198.69 to $652.42 range. That is up +26% on the projected 2030 average. That marks a +194% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, MANE could reach as high as $807.72, with a base case around $421.26 and support toward $226.91 — roughly +252% from $119.60. Momentum favours further upside here.
Expect MANE to range from $229.84 to $882.57 through 2033. The $447.16 average target implies a +274% move from current prices. That is up +6% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The MANE price prediction for 2034 points to an average of $453.25 (low $222.52, high $918.48) — a potential gain of +279% on today's $119.60. Momentum favours further upside here.
In 2035, MANE is projected to trade between $248.66 and $1,100.18, averaging $529.93 — a potential gain of +343% from today's $119.60. That is up +17% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Veradermics, Incorporated's 2040 outlook centres on $964.31, within a $433.94 to $2,210.53 range. That is up +82% on the projected 2035 average. That marks a +706% change versus current levels. Momentum favours further upside here.
By 2050, MANE could reach as high as $5,461.00, with a base case around $2,374.35 and support toward $1,068.46 — roughly +18.9x from $119.60. Buyers look set to stay in control over this stretch.
Investing $1,000 in MANE today (≈ 8.361204 MANE) could be worth
$19,852.4
+$18,852.4 (+1885%) by 2050 · US Dollar
Based on the average projected MANE price of $2,374.35 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in MANEwould be worth at today's price.
$1,000 invested in MANE on Feb 4, 2026 (≈ 26.490066 MANE) would be worth
$3,168.21
+$2,168.21 (+216.8%) today · 3.17× · US Dollar
Based on a MANE entry price of $37.75 vs. today's $119.6.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $129.74 | $921.84 | -7.8% |
| 1 month ago | $92.98 | $1,286.3 | +28.6% |
| 3 months ago | $68.8 | $1,738.37 | +73.8% |
| All time ago | $37.75 | $3,168.21 | +216.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our MANE forecast.
Our base-case forecast reaches $240.00 around 2030.
Implied market cap at $240.00: $10.03B
The multi-year forecast shows a bullish trajectory through 2030, 2040 and 2050. In 2030 the average price is projected at $271.70 with a return on investment of 132.6% and a bullish sentiment. By 2040, the average is $942.30 with a 706.8% ROI and continued bullish sentiment.
By 2050, the average is $2,303.99 with a remarkable 1872.6% ROI, also bullish. The forecast also shows notable intermediate years, such as 2027 with an average of $146.81 and 2028 at $173.60, both bullish, and 2035 with an average of $513.86 and a max of $1,078.47 with a 339.9% ROI and bullish sentiment. These figures are estimates and not guaranteed, and the outlook is subject to market and company-specific risks.
Tap a question to reveal the answer.
The forecasted 2030 average price is $271.70, with a minimum of $159.65 and a maximum of $490.55, and a return on investment of 132.6%. The sentiment is BULLISH.
Forecasts show a bullish sentiment from 2027 onward, with positive ROIs in multiple years (e.g., 2027 ROI 25.7%, 2028 ROI 48.6%, 2029 ROI 72.7%, 2030 ROI 132.6%, continuing bullish thereafter). These are estimates, not guarantees.
Yes. The 2035 forecast shows a maximum of $1,078.47, indicating that $1,000 could be reached within the modeled scenario.
Current price is $116.80 and market cap is $4.88B.
The 2050 forecast shows an average price of $2,303.99, a minimum of $1,036.79, a maximum of $5,299.17, and a ROI of 1872.6%, with a bullish sentiment.
Veradermics, Incorporated Community Discussion
0Share your Veradermics, Incorporated price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.